Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

Max Gelman

Senior Editor

Zachary Brennan

Senior Editor

Alnylam Pharmaceuticals, the pharma market’s leader in RNAi therapies, reported its third quarter earnings Thursday, updating shareholders on its pipeline progress and initial sales figures …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?

Max Gelman

Senior Editor

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Al­ny­lam blames the In­fla­tion Re­duc­tion Act for a PhI­II cut — would it have sold enough for ne­go­ti­a­tions?

Senior Editor

Senior Editor

Sign up to read this article for free.

Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?